SCHEMBL4608372

SCHEMBL4608372

CC(C)Cc1[c]c2ccccc2cc1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6893123 0.85 HTR2A (0.33) HTR2AHTR2CHTR2B
SCHEMBL6885604 0.84 HTR2A (0.32) HTR2AHTR2CHTR2B
SCHEMBL6892427 0.81 DHODH (0.33)
SCHEMBL6892978 0.81 POLB (0.32)
SCHEMBL3672559 0.81 PPARG (0.31) HTR2AHTR2CHTR2B
SCHEMBL6894291 0.79 GRIN2D (0.34)
SCHEMBL66086 0.78 CYP1A2 (0.39)
SCHEMBL11863358 0.77 CYP2A6 (0.32)
SCHEMBL3407567 0.76 HIF1A (0.34)
SCHEMBL258245 0.74 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240241442-A1 Positive Resist Material And Patterning Process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-07-18 US disclosed
US-20240210830-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-27 US disclosed
US-12013639-B2 Positive resist material and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-18 US disclosed
US-20240192591-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-13 US disclosed
US-20240184200-A1 AMINE COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-06 US disclosed
US-20240184199-A1 Onium Salt, Resist Composition, And Patterning Process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-06 US disclosed
US-12001139-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-06-04 US disclosed
CN-118112887-A Resist composition and pattern forming method 信越化学工业株式会社 2024-05-31 CN disclosed
US-20240176238-A1 SULFONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-05-30 US disclosed
US-20240176235-A1 RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-05-30 US disclosed
EP-1023282-A1 NOVEL PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR PREPARATION AND USE AS ECE-INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-08-02 EP disclosed
EP-0997534-A2 Process for the resolution of racemic arylalkylcarboxylic acid esters BASF AKTIENGESELLSCHAFT (DE) 2000-05-03 EP disclosed
EP-0988291-A1 METHOD FOR PRODUCING QUINAZOLINE-DIONES IN SOLID PHASE AND USE OF THE SAME BASF AKTIENGESELLSCHAFT (DE) 2000-03-29 EP disclosed
WO-2000002928-A1 METHOD FOR THE STEREOSELECTIVE PRODUCTION OF GRIGNARD COMPOUNDS AND USE THEREOF BASF AKTIENGESELLSCHAFT (DE) 2000-01-20 WO disclosed
WO-1999051609-A1 METHOD FOR PRODUCING GRIGNARD COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 1999-10-14 WO disclosed
WO-1999019320-A1 NOVEL PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR PREPARATION AND USE AS ECE-INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1999-04-22 WO disclosed
WO-1999019346-A1 DIPEPTIDES FOR THE TREATMENT OF DISEASES RELATED TO THE BIOLOGICAL EFFECT OF ENDOTHELIN BASF AKTIENGESELLSCHAFT (DE) 1999-04-22 WO disclosed
EP-0888262-A1 CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1999-01-07 EP disclosed
WO-1998056770-A1 METHOD FOR PRODUCING QUINAZOLINE-DIONES IN SOLID PHASE AND USE OF THE SAME BASF AKTIENGESELLSCHAFT (DE) 1998-12-17 WO disclosed
WO-1997034852-A1 CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240184199-A1 Onium Salt, Resist Composition, And Patterning Process LBR, ZYX, SCN1B HTR2A 4308/4885HTR2C 4580/4885HTR2B 2888/4885
US-20240176238-A1 SULFONIUM SALT, RESIST COMPOSITION AND PATTERN FORMING PROCESS SLC6A5, HNRNPU, SLC6A9 HTR2A 3133/4885HTR2C 3670/4885HTR2B 3151/4885
US-20240184200-A1 AMINE COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS ADAR, HNRNPU, POLQ HTR2A 361/4885HTR2C 602/4885HTR2B 736/4885
US-12001139-B2 Resist composition and patterning process HNRNPU, HNRNPR, FGR HTR2A 3247/4885HTR2C 3586/4885HTR2B 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.